DL-2-(3'-hydroxypyrid-2'-yl)-4H-5,6-dihydro-1,3-thiazine-4-carboxylic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-2-(3'-hydroxypyrid-2'-yl)-4H-5,6-dihydro-1,3-thiazine-4-carboxylic acid
• 英文别名: 2-(3-hydroxypyridin-2-yl)-5,6-dihydro-4H-1,3-thiazine-4-carboxylic acid
• 化学式: C₁₀H₁₀N₂O₃S
• 分子量: 238.267
• InChiKey: YHYKAOLZIDGFBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  DL-高半胱氨酸 、 2-氰基-3-羟基吡啶 以 甲醇 为溶剂， 反应 4.0h， 以71%的产率得到DL-2-(3'-hydroxypyrid-2'-yl)-4H-5,6-dihydro-1,3-thiazine-4-carboxylic acid
  参考文献：
  名称：

  The Desferrithiocin Pharmacophore

  摘要：

  The (S)-desferrithiocin (DFT) skeleton is shown to be a useful pharmacophore on which to design orally effective iron chelators. While the study clearly indicates that formal reduction of the desazadesmethyldesferrithiocin thiazoline to a thiazolidine (6), expansion of the desmethyldesferrithiocin thiazoline to a thiazine (7), or substitution of the thiazoline sulfur of desazadesmethyldesferrithiocin by an oxygen (8 and 9) lead to a substantial loss of activity, conversion of (S)-desmethyldesferrithiocin (1) to an N-methylhydroxamate (4) or to the hexacoordinate dihydroxamate ligand (5) results in active compounds. This investigation thus demonstrates which structural components of the siderophore are required for iron clearance after oral administration and suggests the use of the desferrithiocin platform as a vector for other chelators.

  DOI：

  10.1021/jm00036a005

文献信息

• Iron binding agents
  申请人：University of Florida

  公开号：US20030083349A1

  公开（公告）日：2003-05-01

  Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a therapeutically-effective amount of a compound of formula (I) or (IV), i.e. sufficient quantity to reduce the population of Plasmodium. The composition of the invention is a compound of formula (I) or (IV) with a pharmaceutical excipient. The article of manufacture is the composition in combination with labeling for treating malaria. The substituents are detailed in the specification.

  本发明涉及一种用于治疗人类患有疟原虫感染的组合物、制品及方法。该方法包括给予化合物(I)或(IV)的治疗有效量，即足够减少疟原虫数量。本发明的组合物是一种含有药用辅料的化合物(I)或(IV)。制品是该组合物与用于治疗疟疾的标签的组合。取代基详见规范。
• Antimalarial agents
  申请人：UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

  公开号：EP1488791A2

  公开（公告）日：2004-12-22

  Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a therapeutically effective amount of a compound of formula (I) or (IV), i.e., sufficient quantity to reduce the population of Plasmodium. The composition of the invention is a compound of formula (I) or (IV) with a pharmaceutical excipient. The article of manufacture is the composition in combination with labelling for treating malaria. The substituents are detailed in the specification.

  本发明描述了用于治疗原生动物疟原虫感染的人类疟疾的组合物、制造品和方法。该方法包括施用治疗有效量的式（I）或（IV）化合物，即足以减少疟原虫数量的量。本发明的组合物是含有药用赋形剂的式 (I) 或 (IV) 化合物。制成品是该组合物与用于治疗疟疾的标签相结合。取代基详见说明书。
• US6864270B2
  申请人：——

  公开号：US6864270B2

  公开（公告）日：2005-03-08
• US7144904B2
  申请人：——

  公开号：US7144904B2

  公开（公告）日：2006-12-05
• US7879886B2
  申请人：——

  公开号：US7879886B2

  公开（公告）日：2011-02-01